CD19
B-lymphocyte antigen CD19
As of the edition of 20 October 2026, CD19 (B-lymphocyte antigen CD19, UniProt P15391) has 22 drugs tested at it and 24 companies on the list, 4 on route A and 8 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P15391
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Immune system; Cancer; Blood and lymph; Infections; Skin and connective tissue; Nervous system; Eye; Urinary and reproductive
- Registered trials of its drugs
- 440
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 7 |
| Went quiet | 2 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 22 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Blinatumomab | Marketed | Phase 4 | Ends 2031 |
| Tafasitamab | Marketed | Phase 3 | Ends 2032 |
| Tisagenlecleucel | Marketed | Phase 3 | Ends 2029 |
| Axicabtagene ciloleucel | Marketed | Phase 4 | Ends 2033 |
| Loncastuximab tesirine | Marketed | Phase 3 | Ends 2033 |
| Lisocabtagene maraleucel | Marketed | Phase 3 | Ends 2033 |
| Inebilizumab | Marketed | Phase 4 | Ends 2032 |
| Brexucabtagene autoleucel | Marketed | Phase 2 | Ends 2032 |
| Budoprutug | Active | Phase 2 | none listed |
| Obecabtagene autoleucel | Marketed | Phase 2 | Ends 2036 |
| Obexelimab | Active | Phase 3 | none listed |
| YK012 | Active | Phase 2 | none listed |
12 of 22 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 8 |
| Engaged | 11 |
| Undetermined | 1 |
| Total on the list | 24 |
The other 21 companies at CD19
In the product24 companies in all; 21 are not named here, and no score is.
See the 24 companies at CD19, ranked, with the facts behind eachRequest access. Nothing is shown until you do.